TWI363630B - Mono-lysine salts of azole compounds - Google Patents

Mono-lysine salts of azole compounds Download PDF

Info

Publication number
TWI363630B
TWI363630B TW095115682A TW95115682A TWI363630B TW I363630 B TWI363630 B TW I363630B TW 095115682 A TW095115682 A TW 095115682A TW 95115682 A TW95115682 A TW 95115682A TW I363630 B TWI363630 B TW I363630B
Authority
TW
Taiwan
Prior art keywords
formula
mono
protecting group
patent application
azole compounds
Prior art date
Application number
TW095115682A
Other languages
English (en)
Other versions
TW200722093A (en
Inventor
Qi Gao
Chung-Pin H Chen
Michael G Fakes
Yadagiri R Pendri
Susanne Kiau
Blisse Vakkalagadda
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of TW200722093A publication Critical patent/TW200722093A/zh
Application granted granted Critical
Publication of TWI363630B publication Critical patent/TWI363630B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰) 7. 一種製備如下式之水溶性單離胺酸鹽之方法:
該方法包含: (a)使式B之化合物與式ΙΙΓ之化合物反應:
B
C1 III' 其中式ΙΙΓ之Pr表示羥基保護基; 該反應在惰性有機溶劑中、在鹼存在下、在約25°C至 50°C之溫度下進行,以形成式IV'之第一中間物: 110271-1011217.doc 丄
IV* 其中式IV·之Pr表示羥基保護基; (b)以有機溶劑移除式IV,之保護基pr ,以形成式V,之第 一中間物:
使式V,之該第二中間物與離胺酸在PH範圍為4.2-5.5 二劑中反應’以生成該單離胺酸鹽。 如%求項7之方法’其中pr之該保護基為第三丁基。 9. 如請求項7 或8之方法,其中步驟(a)中之該溶劑為四氫呋 喃0 1〇_如請求項7-¾。 11 一 虱8之方法,其中步驟(a)中所用該鹼為氫化鈉。 1 1 . 種製備JS iSA· 早離胺酸鹽之乙醇溶劑合物之方法,該單離胺 110271-1011217.d〇c 1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰)
酸鹽具有如下式:
其中單晶胞尺寸 a=9.0314(l)A、b=10.2534(l)人、 c=38.7048(5)A、α=90〇、β=90ο、γ=90ο ;
該方法包含:
Pr〇/ III 其中式ΙΙΓ之Pr表示羥基保護基;該反應在惰性有機 溶劑中、在鹼存在下、在約25°C至50°C之溫度下進行, 以形成式IV’之第一中間物:
S 110271-1011217.doc 1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰)
其中式IV'之Pr表示羥基保護基; (b)以有機溶劑移除式IV1之保護基Pr,以形成式V'之第 二中間物:
V (c) 使式V1之該第二中間物與離胺酸在pH範圍為4.2-5.5 之溶劑中反應,以生成該單離胺酸鹽;以及 (d) 使該單離胺酸鹽在乙醇中結晶以產生該單離胺酸鹽 之乙醇溶劑合物。 12. —種製備單離胺酸鹽之異丙醇溶劑合物之方法,該單離 胺酸鹽具有如下式: 110271-1011217.doc 1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰)
HOOC nh2
CN 其中單晶胞尺寸 a=9.0716(3)A、b=10_3611(3)A c = 38.6521(ll)A、α=90ο、β=90ο、γ=90ο ; 該方法包含: (a)使式Β之化合物與式III’之化合物反應··
CN
III' 其中式ΙΙΓ之Pr表示羥基保護基;該反應在惰性有機 溶劑中、在鹼存在下、在約25°C至50°C之溫度下進行, 以形成式IV’之第一中間物:
S 110271-101I217.doc -7- 1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰)
其中式IV’之Pr表示羥基保護基; (b)以有機溶劑移除式IV'之保護基Pr,以形成式V'之第 二中間物:
V (c) 使式V1之該第二中間物與離胺酸在pH範圍為4.2-5.5 之溶劑中反應,以生成該單離胺酸鹽;以及 (d) 使該單離胺酸鹽在異丙醇中結晶以產生該單離胺酸 鹽之異丙醇溶劑合物。 13. —種製備單離胺酸鹽之正丙醇溶劑合物之方法,該單離 胺酸鹽具有如下式: 11027M011217.doc 1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰)
HOOC nh2
CN 其中單晶胞尺寸 a=9.0728(l)A、b=10.3764(l)A c = 38.7396(5)A、α=90ο、β=90ο、γ=90ο ; 該方法包含: (a)使式Β之化合物與式ΙΙΓ之化合物反應:
Β
CN
III ' 其中式ΙΙΓ之Pr表示羥基保護基;該反應在惰性有機 溶劑中、在鹼存在下、在約25°C至50°C之溫度下進行, 以形成式IV之第一中間物: 110271-1011217.doc 1363630 第095115682號專利申請案 中文申請專利範圍替換本(101年12月17曰)
PrO Ο X
其中式IV'之Pr表示羥基保護基; (b)以有機溶劑移除式IV1之保護基Pr,以形成式V’之第 二中間物:
Ov OH 七》〆
V (C)使式V'之該第二中間物與離胺酸在pH範圍為4.2-5.5 之溶劑中反應,以生成該單離胺酸鹽;以及 (d)使該單離胺酸鹽在正丙醇中結晶以產生該單離胺酸 鹽之正丙醇溶劑合物。 14. 一種如請求項1至3中任一項之單離胺酸鹽之用途,其係 用於製造供治療真菌感染之製劑。 110271-1011217.doc -10-
TW095115682A 2005-05-03 2006-05-03 Mono-lysine salts of azole compounds TWI363630B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67693205P 2005-05-03 2005-05-03

Publications (2)

Publication Number Publication Date
TW200722093A TW200722093A (en) 2007-06-16
TWI363630B true TWI363630B (en) 2012-05-11

Family

ID=36910951

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095115682A TWI363630B (en) 2005-05-03 2006-05-03 Mono-lysine salts of azole compounds

Country Status (34)

Country Link
US (1) US20060264406A1 (zh)
EP (1) EP1877403B1 (zh)
JP (1) JP4015691B1 (zh)
KR (1) KR100887044B1 (zh)
CN (1) CN101213193B (zh)
AR (1) AR053862A1 (zh)
AT (1) ATE503753T1 (zh)
AU (1) AU2006241694B2 (zh)
BR (1) BRPI0610423B8 (zh)
CA (1) CA2606185C (zh)
CY (1) CY1111569T1 (zh)
DE (1) DE602006020998D1 (zh)
DK (1) DK1877403T3 (zh)
EC (1) ECSP077812A (zh)
ES (1) ES2361768T3 (zh)
HK (1) HK1117502A1 (zh)
HR (1) HRP20110467T1 (zh)
IL (1) IL187059A (zh)
JO (1) JO2691B1 (zh)
MX (1) MX2007013605A (zh)
MY (1) MY138095A (zh)
NO (1) NO20075541L (zh)
NZ (1) NZ563092A (zh)
PE (1) PE20071423A1 (zh)
PL (1) PL1877403T3 (zh)
PT (1) PT1877403E (zh)
RS (1) RS51779B (zh)
RU (1) RU2399625C2 (zh)
SA (1) SA06270126B1 (zh)
SI (1) SI1877403T1 (zh)
TW (1) TWI363630B (zh)
UY (1) UY29507A1 (zh)
WO (1) WO2006118351A1 (zh)
ZA (1) ZA200709127B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632842C (en) 2005-12-20 2013-06-25 Eisai R & D Management Co., Ltd. Process for preparation of water-soluble azole prodrugs
CN101389333A (zh) 2006-02-22 2009-03-18 卫材R&D管理有限公司 稳定化药物组合物
CN105287403A (zh) * 2014-08-02 2016-02-03 陕西合成药业股份有限公司 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
WO2019106571A1 (en) 2017-11-28 2019-06-06 Roivant Sciences Gmbh Dosing regimens for the treatment of fungal infections
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0741737T1 (en) * 1994-01-24 2000-02-29 Janssen Pharmaceutica N.V. Watersoluble azole antifungals
NZ270418A (en) * 1994-02-07 1997-09-22 Eisai Co Ltd Polycyclic triazole & imidazole derivatives, antifungal compositions
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
US6265584B1 (en) * 1998-05-22 2001-07-24 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
WO2000030655A1 (en) * 1998-11-20 2000-06-02 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6235728B1 (en) * 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds

Also Published As

Publication number Publication date
RU2007140788A (ru) 2009-06-10
BRPI0610423B1 (pt) 2020-11-10
MX2007013605A (es) 2008-01-24
NO20075541L (no) 2007-11-28
HRP20110467T1 (hr) 2011-07-31
DK1877403T3 (da) 2011-05-09
BRPI0610423B8 (pt) 2021-05-25
HK1117502A1 (en) 2009-01-16
RS51779B (en) 2011-12-31
AU2006241694A1 (en) 2006-11-09
JP4015691B1 (ja) 2007-11-28
EP1877403A1 (en) 2008-01-16
NZ563092A (en) 2010-06-25
IL187059A (en) 2012-08-30
TW200722093A (en) 2007-06-16
BRPI0610423A2 (pt) 2010-06-22
ECSP077812A (es) 2008-01-23
SA06270126B1 (ar) 2009-09-02
JO2691B1 (en) 2013-03-03
AU2006241694B2 (en) 2011-10-20
CN101213193B (zh) 2011-02-02
KR100887044B1 (ko) 2009-03-04
SI1877403T1 (sl) 2011-05-31
PT1877403E (pt) 2011-05-31
MY138095A (en) 2009-04-30
KR20070088460A (ko) 2007-08-29
AR053862A1 (es) 2007-05-23
WO2006118351A1 (en) 2006-11-09
ZA200709127B (en) 2008-07-30
US20060264406A1 (en) 2006-11-23
PE20071423A1 (es) 2006-12-17
PL1877403T3 (pl) 2011-08-31
IL187059A0 (en) 2008-02-09
ES2361768T3 (es) 2011-06-22
CA2606185A1 (en) 2006-11-09
CA2606185C (en) 2012-08-28
JP2008544948A (ja) 2008-12-11
RU2399625C2 (ru) 2010-09-20
EP1877403B1 (en) 2011-03-30
CN101213193A (zh) 2008-07-02
CY1111569T1 (el) 2015-10-07
DE602006020998D1 (de) 2011-05-12
UY29507A1 (es) 2006-11-30
ATE503753T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
TWI363630B (en) Mono-lysine salts of azole compounds
JP3800220B2 (ja) 酢酸アニリド誘導体のα型又はβ型結晶
JP2006518360A (ja) イマチニブの製造方法、及び該方法により製造されたイマチニブ
JP2009533369A5 (zh)
CA2600203A1 (en) New salt and polymorphs of a dpp-iv inhibitor
NZ589497A (en) Process for the synthesis of arformoterol
CA2568897A1 (en) Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states
JP2009513604A5 (zh)
JP6644685B2 (ja) ポマリドミドの調製およびその精製のための改善された方法
JP2010531828A5 (zh)
JP2010521516A5 (zh)
ES2870476T3 (es) Un proceso mejorado para la preparación de diclorhidrato de trientina
US8975405B2 (en) Indenopyridine derivatives
JP4559385B2 (ja) プランルカストまたはその水和物の製造方法、及びその合成中間体
JP2006514956A5 (zh)
JP2010132661A5 (zh)
JP2005517634A5 (zh)
US8598370B2 (en) Process for producing threo-3-(3,4-dihydroxyphenyl)-L-serine
CN105541705B (zh) 一种马来酸氟吡汀化合物的合成方法
CN104016877A (zh) 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
JP2008524327A5 (zh)
JP2008512367A5 (zh)
CA2984961A1 (en) Sodium salt of uric acid transporter inhibitor and crystalline form thereof
JP2008507578A (ja) 塩酸イトプリド中間体としての4−[2−(ジメチルアミノ)エトキシ]ベンジルアミンを製造する方法
JP2012511580A5 (zh)

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees